Fibrotic response after Baerveldt glaucoma drainage device surgery: an initial sight-threatening sign in eyes with refractory childhood glaucoma
PURPOSE: We report the pathological analysis of a postoperative fibrotic reaction as an initial sign of a sight-threatening complication observed during the 2-year outcomes follow up of Baerveldt glaucoma implant (BGI) surgery in eyes with refractory childhood glaucoma. STUDY DESIGN: Retrospective case series. METHODS: Fifteen eyes of 10 patients with refractory childhood glaucoma underwent BGI surgery between 2013 and 2020 at the University of Osaka Hospital. Patients were followed for a minimum of 2 years postoperatively. We investigated the postoperative complications, and histopathologically analyzed the specimens obtained from three eyes with postoperative fibrous membranes on the irises. RESULTS: Nine eyes (60%) had a postoperative fibrous membrane around the tube or on the iris close to the tube, whereas two eyes developed a tractional retinal detachment. The pathological results indicated the tissues were eosinophilic fibrous scar tissues that did not have inflammatory or neoplastic lesions. CONCLUSION: BGI surgery was effective in patients with refractory childhood glaucoma. However, clinicians should be alert to the potential for development of fibrotic ocular inflammation in refractory childhood glaucoma eyes.
Authors
- Takahiro Fujino
- Masako Kurashige (ORCID: https://orcid.org/0000-0001-9212-6644)
- Rumi Kawashima
- Takahiro Matsui (ORCID: https://orcid.org/0000-0002-6753-1688)
- Eiichi Morii (ORCID: https://orcid.org/0000-0001-8490-3650)
- Yuichi Motoyama
- Kenji Matsushita
- Kohji Nishida
Institutions
- Osaka University of Economics (JP)
- Osaka City University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2026-05-02
- DOI
- https://doi.org/10.1007/s10384-026-01357-w
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development